Company Overview and News

 
Earnings misses, tech fragility drag European stocks down

2018-07-30 thehindubusinessline
European shares tumbled from a six-week high on Monday as industrials and tech stocks slipped and disappointing earnings, including from brewer Heineken, dented investors' confidence.
CGEMY CAPMF ICICIBANK DB 532174 IBN TRI CAP AI SBAZ

 
UPDATE 1-Earnings misses and tech fragility drag European stocks down

2018-07-30 reuters
LONDON, July 30 (Reuters) - European shares tumbled from a six-week high on Monday as industrials and tech stocks slipped and disappointing earnings, including from brewer Heineken, dented investors’ confidence.
CGEMY CAPMF GEAGY DB CAP GEAGF AI

5
Final Rule: Revision of the Commission's Auditor Independence Requirements; File No. S7-13-00

2018-07-27 sec.gov
SUMMARY: The Securities and Exchange Commission ("SEC" or "Commission") is adopting rule amendments regarding auditor independence. The amendments modernize the Commission's rules for determining whether an auditor is independent in light of investments by auditors or their family members in audit clients, employment relationships between auditors or their family members and audit clients, and the scope of services provided by audit firms to their audit clients.
CGEMY CAPMF SSREY TWX DTK LNSTY FUTR WM TWC CAP SSREF ACXM

17
Nokia Targets IBM's Blockchain And Watson Cognitive Computing Platforms

2018-04-05 seekingalpha - 1
Blockchain is an incorruptible decentralized ledger for any digital transactions. It has no single point of failure and cannot be controlled by one entity.
IBM CGEMY CAPMF NOK CAP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:CAP / CAP GEMINI on message board site Silicon Investor.

Microcap Kitchen Canadian Stocks Microcap Kitchen Canadian Stocks Microcap Kitchen Canadian Stocks smallcap risk reward potential smallcap risk reward potential smallcap risk reward potential
The Microcap Kitchen: Stocks 5�� to $5 The Microcap Kitchen: Stocks 5�� to $5 The Microcap Kitchen: Stocks 5�� to $5 INO - Inovio Pharmaceuticals - A NYSE Small-Cap INO - Inovio Pharmaceuticals - A NYSE Small-Cap INO - Inovio Pharmaceuticals - A NYSE Small-Cap
The Microcap Basement The Microcap Basement The Microcap Basement Rat dog micro-cap picks... Rat dog micro-cap picks... Rat dog micro-cap picks...
Microcap Potential Homeruns--Credible, and Reporting Microcap Potential Homeruns--Credible, and Reporting Microcap Potential Homeruns--Credible, and Reporting 2018 Canadian Microcap Picku0027em 2018 Canadian Microcap Picku0027em 2018 Canadian Microcap Picku0027em
Til Capital Ltd. Til Capital Ltd. Til Capital Ltd. Ethereum Capital Ethereum Capital Ethereum Capital